Immunotherapy after bladder cancer surgery may reduce recurrence, study shows

New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published in the New England Journal of Medicine.

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *

The information on this site is of a general nature only and is not intended to address the specific circumstances of any particular individual or entity. It is not intended or implied to be a substitute for professional advice. Read more.